Calendario›SNY›Vakzimeter FLU
Vakzimeter FLU
Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants
Ensayo de Sanofi en Influenza Immunization (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 5.000
- Centros
- 1
- Fin del objetivo primario
- feb 2026
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en oct 2024.
Qué mide
Assessing the seasonal influenza vaccination rates among diverse healthy participants 18 years of age through and including 59 years of age (Throughout Study (Approximately 3 months)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroReal-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage. This study aims to address the gap by assessing current influenza vaccination rates, particularly among those aged 60 and older, to inform public health interventions and encourage healthcare providers to recommend influenza vaccination more proactively. The primary objective of this study is to determine the influenza vaccination rates in the German population during the current respiratory season. The study will focus on: 1. Assessing the vaccination rates among the two main age groups 18 years of age through and including 59 years of age and 60 years of age (inclusive) and older 2. Assessing the vaccination rate among individuals with risk-based vaccination recommendation according to Standing Committee on Vaccination (Ständige Impfkommission) (STIKO) The study will target a disproportionate sample of the German population regarding age: 30% aged 18 years of age through and including 59 year of age and 70% aged 60 years of age (inclusive) and older. Within these age groups, the study targets a representative distribution regarding gender and region. This study is conducted as an online survey that will either be self-completed by the respondents (CAWI) or completed via an interviewer for a subgroup of respondents aged 70+ (CATI). The survey is estimated to last 10 minutes and will comprise of closed-ended questions only (i.e., respondents will not have the possibility to add any free-text). The survey will be conducted in German. The panelists will be divided into strata based on demographic variables like gender and region. Within each stratum, participants will be randomly selected to participate in the survey.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06800885), actualizada en mar 2026.